Resolve Therapeutics, a biopharma developing innovative therapies for Systemic Lupus Erythematosus (SLE) and Sjogrens syndrome, will present new data from two clinical studies at the EULAR Annual European Congress of Rheumatology, June 8-11, in London.
The company’s scientific founder Dr. Keith Elkon will deliver the oral presentation “Immune Complex Bound U1 and Y1RNA Correlates with Interferon-Stimulated Gene Expression and Disease Activity: An Observational Study of Systemic Lupus Erythematosus Patients,” 10:50 a.m., June 10.
According to the press release, Resolve Therapeutics’ founder and chief executive officer, Dr. James Posada, will also present the results of the newly completed Phase Ib clinical trial “Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus.” RSLV-132 is Resolve’s lead molecule.
Posada’s presentation, 11:45 a.m., June 9, is titled “Safety, Pharmacokinetics, and Pharmacodynamics of RSLV-132, a Novel RNase-Fc Fusion Protein Developed to Reduce RNA-Containing Immune Complexes in Systemic Lupus Erythematosus.”
The biopharmaceutical is developing additional molecules that contain both RNase and DNase activities – additional potential candidates for the treatment of lupus , Sjogrens syndrome and other autoimmune diseases.
Lupus is a chronic, autoimmune disease that causes damage to any or many parts of a patient’s body including the skin, joints and internal organs. When someone is diagnosed with lupus it means that their immune system no longer fights off viruses, bacteria, germs or other unhealthy invaders.
Normally, the immune systems produces proteins called ‘antibodies’, to protect against outside invaders. An autoimmune disease means the body has stopped being able to distinguish the invaders from healthy tissues, so it creates antibodies that attack and damage healthy tissue. The antibodies may cause inflammation, pain and organ disorder anywhere in the body.
Sjogren’s syndrome is a disorder of the immune system characterized by two particular symptoms: dry eyes and dry mouth. It is usually a disease associated with other immune system disorders, such as lupus, when the mucous membranes and moisture-secreting glands of the eyes and mouth are typically attacked first, leading to a reduced production of tears and saliva. Available treatments target the relief of associated symptoms.